These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 17005526)

  • 21. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
    Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
    Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.
    Cappelli G; Bandiani G; Cancarini GC; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
    Adv Perit Dial; 1999; 15():238-42. PubMed ID: 10682110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Free water transport in children on peritoneal dialysis is higher with more biocompatible dialysis solutions, higher with older age and declines with time.
    Raaijmakers R; Coester A; Smit W; Krediet RT; Schröder CH
    Nephrol Dial Transplant; 2012 Mar; 27(3):1183-90. PubMed ID: 21771747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.
    Pajek J; Kveder R; Bren A; Gucek A; Bucar M; Skoberne A; Waniewski J; Lindholm B
    Nephrol Dial Transplant; 2009 May; 24(5):1617-25. PubMed ID: 19066345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.
    Lee HY; Choi HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Kim MJ; Shin SK
    Nephrol Dial Transplant; 2006 Oct; 21(10):2893-9. PubMed ID: 16957012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
    Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
    Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial.
    Jiang N; Qian J; Sun W; Lin A; Cao L; Wang Q; Ni Z; Wan Y; Linholm B; Axelsson J; Yao Q
    Nephrol Dial Transplant; 2009 Aug; 24(8):2551-8. PubMed ID: 19258386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of peritoneal transport rate and dialysis adequacy with inflammation in peritoneal dialysis patients.
    Fein PA; Fazil I; Rafiq MA; Schloth T; Matza B; Chattopadhyay J; Avram MM
    Adv Perit Dial; 2006; 22():2-6. PubMed ID: 16983929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exfoliated mesothelial cell and CA-125 in automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD) patients.
    Kanjanabuch T; Puttipittayathorn N; Leelahavanichkul A; Lieusuwan S; Katavetin P; Mahatanan N; Sriudom K; Chirananthavat T; Thongbor N; Eiam-Ong S
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S119-25. PubMed ID: 22043578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
    Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
    Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.
    Rodrigues AS; Almeida M; Fonseca I; Martins M; Carvalho MJ; Silva F; Correia C; Santos MJ; Cabrita A
    Nephrol Dial Transplant; 2006 Mar; 21(3):763-9. PubMed ID: 16332703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
    Park JW; Kang SH; Do JY
    Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midpeliq reduces glucose load.
    Itami N; Tsuji Y; Katsuki Y; Ohira S
    Adv Perit Dial; 2003; 19():236-9. PubMed ID: 14763070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acid-base balance in peritoneal dialysis patients: a Stewart-Fencl analysis.
    Klaboch J; Opatrná S; Matousovic K; Sefrna F; Havlín J; Schück O
    Ren Fail; 2009; 31(8):625-32. PubMed ID: 19817518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
    Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
    Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
    Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
    Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model.
    Kim CD; Kwon HM; Park SH; Oh EJ; Kim MH; Choi SY; Choi MJ; Kim IS; Park MS; Kim YJ; Kim YL
    Ther Apher Dial; 2007 Feb; 11(1):56-64. PubMed ID: 17309576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
    Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
    Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.